BSX Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.…
Industry Peers
Medical DevicesKey Statistics
About Boston Scientific (NYSE: BSX)
›
Boston Scientific (NYSE: BSX) is listed on the New York Stock Exchange, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 59,000 employees.
The shares were at 42.99 USD on 19 November 2026, down 58.1% over 52 weeks. Its 52-week range is 39.57 USD to 102.71 USD: the price is 58.1% below the high and 8.6% above the low.
At a market capitalisation of 62.31B USD, it trades at 18.1 times trailing earnings and 13.7 times forward earnings. The median trailing P/E of its 19 largest Medical Devices peers is 25.6, a discount of 29% for BSX.
Boston Scientific reports return on equity of 12.0%, an operating margin of 19.6% and revenue up 1.4% year over year.
Its debt exceeds its cash by 11.34B USD, a debt-to-equity ratio of 0.47. Its Piotroski F-score is 9 out of 9, a strong reading of its financial health. 28 analysts cover the stock, with an average rating of Buy; their mean price target of 49.60 USD is 15.4% above the current price. The next earnings report is expected on 10 February 2027.